FOGHORN THERAPEUTICS INC. - COMMON STOCK

Foghorn Therapeutics Highlights Clinical Program Updates and Research Progress and Provides Strategic Objectives for 2024

08 Jan 2024 07:00:00 By Nasdaq GlobeNewswire

Foghorn Therapeutics Announces CFO Departure

03 Jan 2024 16:05:00 By Nasdaq GlobeNewswire

Foghorn Therapeutics Announces Clinical Data from Phase 1 Study of FHD-286, a Novel BRG1/BRM Inhibitor, in Patients with Advanced Hematologic Malignancies, to be Presented at American Society of Hematology Annual Meeting

01 Dec 2023 07:00:00 By Nasdaq GlobeNewswire

Foghorn Therapeutics Provides Third Quarter 2023 Financial and Corporate Update

02 Nov 2023 07:00:00 By Nasdaq GlobeNewswire

Foghorn Therapeutics to Present at Upcoming Conferences Including New Preclinical Data from EP300 and CBP Selective Degrader Programs

24 Oct 2023 08:00:00 By Nasdaq GlobeNewswire

Foghorn Therapeutics Announces Clinical Data From Phase 1 Study of FHD-286 in Metastatic Uveal Melanoma to Be Presented at ESMO Congress

13 Oct 2023 08:00:00 By Nasdaq GlobeNewswire

Foghorn Therapeutics to Present Clinical and Pre-Clinical Data from Multiple Programs Across Its Diverse Pipeline at AACR-NCI-EORTC International Conference

04 Oct 2023 08:00:00 By Nasdaq GlobeNewswire

Foghorn Therapeutics Announces Participation in Upcoming Investor Conferences

05 Sep 2023 08:00:00 By Nasdaq GlobeNewswire

Foghorn Therapeutics Announces First Patient Dosed in Phase 1 Combination Study of FHD-286 for Relapsed and/or Refractory AML

31 Aug 2023 07:00:00 By Nasdaq GlobeNewswire

Foghorn Therapeutics Announces Chief Medical Officer Succession

08 Aug 2023 07:00:01 By Nasdaq GlobeNewswire

Foghorn Therapeutics Provides Second Quarter 2023 Financial and Corporate Update

04 Aug 2023 07:00:00 By Nasdaq GlobeNewswire

Foghorn Therapeutics Announces Clinical Data from Phase 1 Study of FHD-286 in Metastatic Uveal Melanoma

28 Jun 2023 07:00:00 By Nasdaq GlobeNewswire

Foghorn Therapeutics Announces Participation in Upcoming Investor Conferences

07 Jun 2023 08:00:01 By Nasdaq GlobeNewswire

Foghorn Therapeutics Announces FDA Has Lifted Clinical Hold on Phase 1 Study of FHD-286 in Relapsed and/or Refractory AML/MDS Patients

05 Jun 2023 07:00:01 By Nasdaq GlobeNewswire

Foghorn Therapeutics Provides First Quarter 2023 Financial and Corporate Update

08 May 2023 07:00:00 By Nasdaq GlobeNewswire

Foghorn Therapeutics to Participate at the H.C. Wainwright BioConnect Investor Conference

25 Apr 2023 16:05:00 By Nasdaq GlobeNewswire

Foghorn Therapeutics Provides an Update on FHD-609

24 Apr 2023 07:00:00 By Nasdaq GlobeNewswire

Foghorn Therapeutics to Present Preclinical Data from Its Selective CBP and EP300 Protein Degrader Programs and Preclinical Data for FHD-286, a Potent, Selective Inhibitor of BRG1 and BRM, at the 2023 American Association for Cancer Research Annual Meeting

10 Apr 2023 16:05:00 By Nasdaq GlobeNewswire

Foghorn Therapeutics to Highlight Transcription Factor and Protein Degradation Capabilities at the 18th Annual Drug Discovery Chemistry Meeting

06 Apr 2023 16:05:00 By Nasdaq GlobeNewswire

Foghorn Therapeutics Provides 2023 Outlook and Full Year 2022 Corporate Update

09 Mar 2023 07:00:00 By Nasdaq GlobeNewswire